A 2014 phase I study showed that BRCA1/2 breast cancer patients had a 71% response rate (12/17 patients) to olaparib (50 mg BID) and cisplatin (60 mg/m2) combination therapy. This evidence concerns the gene BRCA1 and breast cancer.